Dexmedetomidine for Sedation During Radiological Interventional Procedures

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute, Egypt
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Age from 18-65 years old

• ASA physical status of I-II

• Expected procedure lasting at least 30 minutes

Exclusion Criteria:

• Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block.

• An alpha2-agonist or antagonist within 14 days before the scheduled procedure.

• patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration.

• Patients who are allergic to Dexmedetomidine or alpha 2-agonists.